Primary patency ( · people with PAD
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Technical success · patients with symptomatic Iliac artery lesions
1 finding from 1 review
Incidence of complications (immediate) · patients with symptomatic Iliac artery lesions
1 finding from 1 review
Improvement in the stage of PAD according to Rutherford's criteria (one year) · patients with symptomatic Iliac artery lesions
Angioplasty showed no clear difference in improvement in the stage of PAD according to Rutherford's criteria… compared with primary stenting (low certainty).
1 finding from 1 review
Primary patency ( · patients with symptomatic Iliac artery lesions
Angioplasty showed no clear difference in primary patency (two years) compared with primary stenting (low certainty).
1 finding from 1 review
Reintervention · patients with symptomatic Iliac artery lesions
Angioplasty showed no clear difference in reinterventions (six to eight years) compared with primary stenting (low certainty).
1 finding from 1 review
Resolution of symptoms and signs (one year) · patients with symptomatic Iliac artery lesions
Angioplasty showed no clear difference in resolution of symptoms and signs (one year) compared with primary stenting (low certainty).
1 finding from 1 review
Improvement in walking distance as reported by the patient · patients with symptomatic Iliac artery lesions
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
DOAC showed no clear difference in symptomatic VTE compared with placebo (low certainty).
1 finding from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin probably leads to lower symptomatic PE compared with no thromboprophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin leads to lower symptomatic DVT compared with no thromboprophylaxis (high certainty).
1 finding from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin leads to lower any VTE compared with no thromboprophylaxis (high certainty).
1 finding from 1 review
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with no thromboprophylaxis (low certainty).
1 finding from 1 review
Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin probably leads to higher clinically relevant bleeding compared with no thromboprophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in symptomatic VTE compared with with active control (1) (low certainty).
3 findings from 1 review
RR 2.89 [0.12, 66.75]
1 study · 51 participants
Low
RR 0.51 [0.22, 1.17]
2 studies · 781 participants
Moderate
RR 0.33 [0.14, 0.83]
1 study · 439 participants
High
Major bleeding · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with with active control (1); GRADE not reported.
3 findings from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in any VTE compared with with active control (1); GRADE not reported.
3 findings from 1 review
RR 4.81 [0.24, 95.58]
Studies not reported
GRADE not reported
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Major bleeding · ambulatory cancer patients receiving chemotherapy
DOAC showed no clear difference in major bleeding compared with placebo (moderate certainty).
1 finding from 1 review